MeiraGTx Sales Jump 1,133 Percent
MeiraGTx Plc (NASDAQ:MGTX), a biotechnology company specializing in gene therapies for neurodegenerative, ocular, and glandular disorders, released its second quarter results on August 14, 2025. The key news centered on a sizable year-over-year revenue gain (GAAP)—reflecting progress in manufacturing work for major partners—but results fell significantly short of estimates. The company reported GAAP revenue of $3.7 million against an expected $6.48 million. Earnings per share (GAAP) were $(0.48). Despite progress in its research and regulatory pipeline, Ongoing GAAP net losses and a sharp decline in cash reserves underscored continued financial pressures during the period.
Source: Analyst estimates for the quarter provided by FactSet.
MeiraGTx Plc develops gene therapies to address complex diseases impacting the nervous system, eyes, and salivary glands. Its core business focuses on designing, manufacturing, and advancing gene-based medicines through clinical trials into commercial use. The company has invested heavily in specialized production sites, giving it tight control over product quality and the ability to scale both in-house and for third parties.
Source Fool.com
